Literature DB >> 29573551

Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation.

S Sandy An1, C Patrick Henson2, Robert E Freundlich2, Matthew D McEvoy3.   

Abstract

A 66-year-old man with cryptogenic cirrhosis secondary to nonalcoholic steatohepatitis presented for orthotopic liver transplantation. Following organ reperfusion, the patient developed vasoplegic syndrome, with arterial blood pressures of approximately 60-70/30-40 mm Hg (mean arterial pressure [MAP] <45 mm Hg) for >90 minutes. He required high-dose norepinephrine and vasopressin infusions, as well as i.v. bolus doses of norepinephrine and vasopressin to reach a goal MAP> 60 mm Hg. There was minimal response to a 2 mg/kg i.v. bolus of methylene blue. Following the administration of 5 g of i.v.hydroxocobalamin, the patient had a profound improvement in arterial blood pressure, with subsequent discontinuation of the vasopressin infusion and rapid reduction of norepinephrine infusion from 20 to 2 μg/min. While there have been several reports of the efficacy of hydroxocobalamin for vasoplegia after cardiopulmonary bypass, there have been only limited cases of hydroxocobalamin used in liver transplantation, and none with high-dose administration. We present a case of vasoplegic syndrome during liver transplantation that was refractory to high-dose vasopressors and methylene blue but responsive to high-dose i.v. hydroxocobalamin.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  anesthesia/pain management; clinical research/practice; liver disease; liver transplantation: auxiliary; off-label drug use; physician education

Year:  2018        PMID: 29573551      PMCID: PMC6138872          DOI: 10.1111/ajt.14736

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  17 in total

1.  Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation.

Authors:  Gregory W Fischer; Ylva Bengtsson; Suzanne Scarola; Edmond Cohen
Journal:  J Cardiothorac Vasc Anesth       Date:  2008-10-04       Impact factor: 2.628

2.  Treatment of Vasoplegic Syndrome With Intravenous Hydroxocobalamin During Liver Transplantation.

Authors:  Brent T Boettcher; Harvey J Woehlck; Sarah E Reck; Johnny C Hong; Michael A Zimmerman; Joohyun Kim; M Tracy Zundel; Julie K Freed; Paul S Pagel
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-10-14       Impact factor: 2.628

Review 3.  Vasoplegic syndrome: An update on perioperative considerations.

Authors:  Henry Liu; Ling Yu; Longqiu Yang; Michael S Green
Journal:  J Clin Anesth       Date:  2017-08       Impact factor: 9.452

4.  Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels.

Authors:  Asif K Mustafa; Gautam Sikka; Sadia K Gazi; Jochen Steppan; Sung M Jung; Anil K Bhunia; Viachaslau M Barodka; Farah K Gazi; Roxanne K Barrow; Rui Wang; L Mario Amzel; Dan E Berkowitz; Solomon H Snyder
Journal:  Circ Res       Date:  2011-10-06       Impact factor: 17.367

5.  Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity.

Authors:  Harvey K Rosenbaum; P Ken Gillman
Journal:  A A Case Rep       Date:  2016-07-01

6.  Hydroxocobalamin for Vasoplegic Syndrome in Liver Transplantation: Restoration of Blood Pressure Without Vasospasm.

Authors:  Harvey J Woehlck; Brent T Boettcher; Kathryn K Lauer; David C Cronin; Johnny C Hong; Michael A Zimmerman; Joohyun Kim; Motaz Selim
Journal:  A A Case Rep       Date:  2016-12-15

7.  The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation.

Authors:  Heike Koelzow; Jacqueline A Gedney; Janos Baumann; Nicola J Snook; Mark C Bellamy
Journal:  Anesth Analg       Date:  2002-04       Impact factor: 5.108

Review 8.  Vasoplegic syndrome--the role of methylene blue.

Authors:  Ganesh Shanmugam
Journal:  Eur J Cardiothorac Surg       Date:  2005-09-06       Impact factor: 4.191

Review 9.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

10.  Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1β, TNF-α, IL-6, and HMGB1 expression.

Authors:  André L F Sampaio; Jesmond Dalli; Vincenzo Brancaleone; Fulvio D'Acquisto; Mauro Perretti; Carmen Wheatley
Journal:  Mediators Inflamm       Date:  2013-05-28       Impact factor: 4.711

View more
  2 in total

Review 1.  Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.

Authors:  Theresa J Barnes; Maxwell A Hockstein; Craig S Jabaley
Journal:  SAGE Open Med       Date:  2020-06-25

2.  High-dose hydroxocobalamin in end-stage liver disease and liver transplantation.

Authors:  Sujit Vijay Sakpal; Hannah Reedstrom; Cody Ness; Tobin Klinkhammer; Hector Saucedo-Crespo; Christopher Auvenshine; Robert N Santella; Jeffery Steers
Journal:  Drugs Ther Perspect       Date:  2019-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.